StreetInsider.com News Articles

Increasing unusual call volume: CYPH BMEA KHC DPRO CBRG NAVN TTAN RARE SOLZ TSSI AADX BEAM AVAV

Thu, 10 Sep 2026 09:58:19 -0400

Increasing unusual call volume: CYPH BMEA KHC DPRO CBRG NAVN TTAN RARE SOLZ TSSI AADX BEAM AVAV

Biomea Fusion, Inc. (BMEA) January 2.5 calls active

Tue, 08 Sep 2026 05:30:01 -0400

Biomea Fusion, Inc. (NASDAQ: BMEA) 30-day option implied volatility is at 108; compared to its 52-week range of 55 to 189 with a focus on January 2.5 calls.

Increasing unusual call option volume: GPRO BMEA DPRO RARE INSW VSXY CHPT VRNS SYF EPYT

Tue, 08 Sep 2026 04:44:53 -0400

Increasing unusual call option volume: GPRO BMEA DPRO RARE INSW VSXY CHPT VRNS SYF EPYT

Biomea Fusion to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences:

Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
H.C. Wainwright 28^th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings

Biomea Fusion to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
H.C. Wainwright 28^th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings

H.C. Wainwright on Biomea Fusion Inc. (BMEA) amid 17% Gain: 'Another step toward confirmatory Phase 2 data and T2D development strategy'

Mon, 24 Aug 2026 09:43:57 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $4.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).

The analyst comments "Another step toward confirmatory Phase 2 data and T2D development strategy. This morning, Biomea announced completion of enrollment in the Phase 2 COVALENT-211 trial evaluating icovamenib in insulin-deficient T2D patients (SIDD), who are not achieving glycemic targets despite SoC antihyperglycemic medications. COVALENT-211 enrolled 64 participants across 18 clinical sites, randomized to receive either icovamenib (100 mg, once daily), or placebo (2:1), for 12 weeks as an add-on to stable background therapy, followed by a 40-week off-treatment period designed to

H.C. Wainwright on Biomea Fusion Inc. (BMEA) amid 17% Gain: 'Another step toward confirmatory Phase 2 data and T2D development strategy'

Mon, 24 Aug 2026 09:43:57 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $4.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).

Biomea Fusion completes enrollment in Phase II diabetes trial

Mon, 24 Aug 2026 07:03:07 -0400

Biomea Fusion, Inc. (Nasdaq: BMEA) announced the completion of enrollment in COVALENT-211, a Phase II clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (T2D) who remain inadequately controlled on standard-of-care antihyperglycemic therapies.

The trial enrolled 64 participants across 18 clinical sites. Participants were randomized 2:1 to receive either icovamenib 100 mg once daily or placebo for 12 weeks as an add-on to stable background therapy, followed by a 40-week off-treatment period. The primary endpoint will be assessed at Week 26, with secondary endpoint follow-up through Week 52. The company anticipates reporting topline Week 26 results in the first

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Mon, 24 Aug 2026 07:00:00 -0400

Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027
COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027
These ongoing Phase II diabetes trials target two distinct T2D populations that demonstrated durable glycemic improvements following 12 weeks of icovamenib treatment in COVALENT-111

SAN CARLOS, Calif., Aug. 24, 2026

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Mon, 24 Aug 2026 07:00:00 -0400

Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027
COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027
These ongoing Phase II diabetes trials target two distinct T2D populations that demonstrated durable glycemic improvements following 12 weeks of icovamenib treatment in COVALENT-111

SAN CARLOS, Calif., Aug. 24, 2026

Biomea Fusion doses first patient in obesity combo drug study

Thu, 13 Aug 2026 07:02:31 -0400

Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the first participant has been dosed in a new arm of the OPAL platform research study, evaluating its investigational compound icovamenib in combination with low-dose semaglutide in people who are overweight or obese without type 2 diabetes.

The study arm is being conducted in collaboration with the University of Leicester and the Leicester Diabetes Centre, led by Professor Dame Melanie Davies and Professor Thomas Yates, alongside the NIHR Biomedical Research Centre Leicester.

The randomized, double-blind study arm plans to enroll 64 participants split equally between two groups: one receiving icovamenib (100mg, once daily for 12

Biomea Fusion doses first patient in obesity combo drug study

Thu, 13 Aug 2026 07:02:31 -0400

The randomized, double-blind study arm plans to enroll 64 participants split equally between two groups: one receiving icovamenib (100mg, once daily for 12

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Thu, 13 Aug 2026 07:00:00 -0400

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes

SAN CARLOS, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Optimizing Physical Function with Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial (“OPAL”). The study is being conducted in collaboration with

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Thu, 13 Aug 2026 07:00:00 -0400

Citi opens 90-day Positive catalyst watch on Biomea Fusion

Tue, 11 Aug 2026 04:48:03 -0400

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $7.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).

The analyst noted that timelines for icovamenib's Phase 2 26-week Type 2 diabetes data have been pushed back due to enrollment pace. Data from the COVALENT-211 trial in insulin-deficient patients is now expected in the first quarter of 2027, moved from the fourth quarter of 2026. Data from the COVALENT-212 trial, targeting patients uncontrolled on GLP-1-based therapy, is now expected in the second quarter of 2027, also shifted from the fourth quarter of 2026.

Management has described the COVALENT-211 study as a key milestone,

Biomea Fusion, Inc. (BMEA) Tops Q2 EPS by 9c

Wed, 05 Aug 2026 18:18:31 -0400

Biomea Fusion, Inc. (NASDAQ: BMEA) reported Q2 EPS of ($0.12), $0.09 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Biomea Fusion, Inc. (BMEA) click here.

Form 10-Q Biomea Fusion, Inc. For: Jun 30

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874233.html

Form 10-Q Biomea Fusion, Inc. For: Jun 30

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874233.html

Form 8-K Biomea Fusion, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874152.html

Form 8-K Biomea Fusion, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874152.html

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in